Last reviewed · How we verify
Paclitaxel for Injection
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.
At a glance
| Generic name | Paclitaxel for Injection |
|---|---|
| Also known as | Tesu |
| Sponsor | Bio-Thera Solutions |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin; microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane that binds to the β-subunit of tubulin dimers and stabilizes microtubule polymers, preventing their normal dynamic instability. This disruption of microtubule dynamics leads to mitotic arrest in the G2/M phase of the cell cycle and triggers apoptosis in rapidly dividing cancer cells. It is effective against a broad range of solid tumors.
Approved indications
- Metastatic carcinoma of the ovary
- Breast cancer (metastatic and adjuvant)
- Non-small cell lung cancer
- Kaposi's sarcoma
- Other solid tumors (in development or approved use)
Common side effects
- Neutropenia
- Peripheral neuropathy
- Myalgia/arthralgia
- Alopecia
- Nausea/vomiting
- Diarrhea
- Hypersensitivity reactions
- Mucositis
Key clinical trials
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel for Injection CI brief — competitive landscape report
- Paclitaxel for Injection updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI